Your browser doesn't support javascript.
loading
Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study.
Sjöqvist, Urban; Tribukait, Bernhard; Ost, Ake; Einarsson, Curt; Oxelmark, Lena; Löfberg, Robert.
Afiliação
  • Sjöqvist U; Department of Medicine, Stockholm South Hospital, Karolinska Institutet, Stockholm, Sweden. urban.sjoqvist@sos.sll.se
Anticancer Res ; 24(5B): 3121-7, 2004.
Article em En | MEDLINE | ID: mdl-15510599
ABSTRACT
BACKGROUND &

AIMS:

There is an increased risk of colorectal carcinoma (CRC) in patients with longstanding, extensive colonic inflammatory bowel disease (IBD). Primary sclerosing cholangitis, family history of CRC, mucosal dysplasia and DNA-aneuploidy are other risk factors. Recently, results from animal studies have shown that the bile acid ursodeoxycholic acid (UDCA) has a favourable impact on experimentally-induced CRC/neoplasia in rats. The aim of this proof of the concept study was to explore the possible preventive/reverting effects of UDCA in patients with colorectal IBD with existing findings of low grade dysplasia and/or DNA-aneuploidy. PATIENTS AND

METHODS:

Nineteen patients (13 UC, 6 CD, median age 43 years) with long-standing, extensive IBD (median duration 21 years), with previous findings of low-grade dysplasia and/or DNA-aneuploidy, were randomized to receive either UDCA (500 mg b.i.d) (n=10) or placebo (n=9) in a controlled, double-blind, two-year study. Colonoscopy with multiple biopsies for histopathology and for DNA-flow cytometry was performed at the start and at six-month intervals during the study period. The primary outcome was the need for colectomy due to progression of dysplasia. Changes in dysplasia and DNA-aneuploidy scores were also assessed.

RESULTS:

There were no significant differences in the overall composed score between the two groups, either at study start or during the study period. In the placebo group one patient had a progression of dysplasia into high-grade and one patient developed DALM with low-grade dysplasia; both had a colectomy. In contrast, no UDCA-treated patient had progression of dysplasia.

CONCLUSION:

UDCA may prevent further progression of manifest low-grade dysplasia in colorectal IBD. Prolonged treatment or an increased dose may be needed to fully exploit the chemopreventive properties of this compound.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Lesões Pré-Cancerosas / Ácido Ursodesoxicólico / Colagogos e Coleréticos / Neoplasias Colorretais / Colite Ulcerativa / Doença de Crohn / Aneuploidia Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2004 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Lesões Pré-Cancerosas / Ácido Ursodesoxicólico / Colagogos e Coleréticos / Neoplasias Colorretais / Colite Ulcerativa / Doença de Crohn / Aneuploidia Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2004 Tipo de documento: Article